|
|
by Claremont Creek Alerts on January 18th, 2012 
January 18, 2012 source: MedCity News
Personalized medicine company AssureRx Health has released the next-generation version of its genetic screening test for psychiatric drugs.
The Cincinnati-area company’s GeneSightRx test, which helps doctors pick the right psychiatric drugs for patients based on their genes, was launched in 2009. The test uses a cheek swab, mathematical algorithms and bioinformatics to narrow drug choices to those that work with a patient’s genes.
. . .
→ Read full post: Claremont Creek Ventures’ portfolio company AssureRX updates its psychiatric drugs screening test
by Claremont Creek Alerts on December 15th, 2011 
September 9, 2011 source: originally published in the San Francisco Business Times
Photo: Spencer Brown The winner “is the company that’s going to help families,” says GSN CEO Rabinowitz.
Gene Security Network’s race to develop safer, more accurate prenatal test is all business for Matt Rabinowitz — and it’s personal.
A relative of Rabinowitz, Gene Security Network’s CEO, took a blood test for the likelihood of Down’s syndrome in her unborn baby and . . .
→ Read full post: Claremont Creek Ventures’ portfolio company Gene Security Network in race for prenatal test
by John Steuart on September 12th, 2011 
Claremont Creek Ventures portfolio company Gene Security Network (GSN) achieved a technical breakthrough that even Dear Abby can crow about. Never before, have scientists and clinicians been about to measure fetal DNA in a pregnant woman’s blood with enough accuracy to determine paternity or relevant information about the baby in utero — until now. If you are curious why this service might be helpful, see Dear Abby’s recent column below.
In . . .
→ Read full post: Why Dear Abby loves this company (and you should, too)
by Brad Webb on September 12th, 2011 
It is always great to brag and cheer about one of our portfolio companies. Working with portfolio companies to help them succeed is one of a VC’s key jobs, and helping build an executive team is an area where a VC can help a lot. We are pleased to announce that AssureRx Health has just added some super people to its team. The three executives are: Dr. C. Anthony Altar, PhD, chief science officer; . . .
→ Read full post: Claremont Creek Ventures portfolio company AssureRx Health expands senior management team
by John Steuart on August 29th, 2011 
Successful venture capital investing in molecular diagnostics requires proper commercialization of innovation. But how does this innovation get brought to market? The panel will explore the challenges of commercialization in a still-difficult business environment.
These challenges include the cost-efficient development of technology that is truly disruptive yet cost-competitive. Panelists will discuss how to best determine the size of a market and how to assess a competitive landscape.
Startups that surmount these challenges then have . . .
→ Read full post: Sam Colella of Versant Ventures, Risa Stack of Kleiner Perkins and Alex de Winter of Mohr Davidow join me for the Molecular Diagnostics World Congress Event on September 29 at 5:15pm
by Brad Webb on July 6th, 2011 July 1, 2011 source: Genetic Engineering & Biotechnology News by Brad Webb
Rapid Transition from Laboratory Discoveries to Commercialization Is Transforming Healthcare
It’s been less than a decade since a full human genome was sequenced, but already there is talk that the promise of genomics-inspired personal medicine is not being realized. I couldn’t disagree more. As we point out in this article, cardiologists, psychiatrists, and internists can now order quick and inexpensive genetics-based screening . . .
→ Read full post: Moving Quickly from an Idea to a Product
John Steuart was a panelist at The Deal’s webcast audio seminar:
Technology Transfer in the 21st Century, on May 12, 2011
(also participating as a panelist – Jeff Jensen, CEO, Fluxion Biosciences Inc. a Claremont Creek Ventures portfolio company)
A recording of the seminar is now available to play online or download through 8/12/2011.
Click here to access the recording. The slides from the webcast are . . .
→ Read full post: Recording of “Technology Transfer in the 21st Century” webcast available
May 11, 2011 source: Wall Street Journal Health Blog
Public Education and Gene Testing to Improve Medication Adherence
There are tons of reasons why people don’t take the medications they’ve been prescribed, including side effects, cost and complicated drug regimens.
A couple of different approaches to improving adherence are in the news today. The first is Script Your Future, a multi-year public-education campaign spearheaded by the National Consumers League and supported by health-industry companies, . . .
→ Read full post: Claremont Creek Ventures portfolio company AssureRx featured in WSJ article
by Claremont Creek Alerts on April 6th, 2011 April 5, 2011 source: Gene Security Network press release
Gene Security Network (GSN) welcomes the birth of the first baby to be born following the use of GSN’s novel Parental SupportTM technology for single gene preimplantation genetic diagnosis (PGD) and concurrent 24-chromosome screening. This test allows couples who are at risk to have children with genetic disease to undergo embryo testing during an in vitro fertilization (IVF) cycle in order to . . .
→ Read full post: Claremont Creek Ventures portfolio company GSN’s testing technology helps couple achieve their dream of a healthy child
by Claremont Creek Alerts on March 25th, 2011 March 25, 2011 source: VentureWire by Timothy Hay
AssureRx Health Inc. has raised an $11 million Series B round from Sequoia Capital and Claremont Creek Ventures for its testing system that helps psychiatric patients find the most compatible medications, according to an investor.
“This could be one of the biggest diagnostic companies of the decade, in my estimation,” said John Steuart, a Claremont Creek co-founder and managing director who takes . . .
→ Read full post: AssureRx Pulls Together $11M For Psych Diagnostics
|
